以肠促胰岛素为基础的肥胖管理药物的营养挑战:对临床实践的影响。

IF 9.2
Tair Ben-Porat, Shiri Sherf-Dagan, Marilou Côté, Cherie Josephine Miner, Assaf Buch
{"title":"以肠促胰岛素为基础的肥胖管理药物的营养挑战:对临床实践的影响。","authors":"Tair Ben-Porat, Shiri Sherf-Dagan, Marilou Côté, Cherie Josephine Miner, Assaf Buch","doi":"10.1016/j.advnut.2025.100522","DOIUrl":null,"url":null,"abstract":"<p><p>Several novel incretin-based obesity management medications (OMMs) have been recently approved for chronic weight management in adults with obesity or overweight. These agents have demonstrated substantial weight reduction effects, alongside glucoregulatory and cardioprotective benefits. However, the use of incretin-based OMMs presents nutritional challenges that remain insufficiently addressed. These include side effects such as gastrointestinal (GI) disturbances and loss of lean body mass (LBM), which may compromise nutritional status, reduce energy expenditure, and heighten the risk of rebound weight gain, sarcopenia, and frailty. Moreover, while these medications effectively suppress energy intake and reduce food quantity, they may also have unintended effects on diet quality, potentially influencing macronutrient distribution, ultra processed food consumption, risk of vitamin and mineral deficiencies, and disordered eating behaviors, which could undermine long-term weight maintenance and the cardiometabolic benefits achieved through these pharmacotherapy agents. Emerging evidence suggests that specific dietary and behavioral strategies, such as higher protein intake, resistance training, nutrient-dense eating patterns, and fostering adaptive eating behaviors, may help mitigate nutritional challenges and physiological deterioration during significant weight reduction, while also supporting cardiometabolic health maintenance. However, the application of these strategies as adjunct treatments alongside the new OMMs remains unclear. This narrative review summarizes the current literature on these issues and proposes dietary interventions and behavioral modification strategies aimed at mitigating the adverse effects that can be associated with incretin-based OMMs. These considerations are increasingly important given the expanding use of these medications, the degree of weight reduction they induce, and the implications for specific at-risk groups, including aging populations prone to muscle and functional decline, individuals with pre-existing conditions of nutritional deficiencies, chronic diseases, and disordered eating patterns.</p>","PeriodicalId":72101,"journal":{"name":"Advances in nutrition (Bethesda, Md.)","volume":" ","pages":"100522"},"PeriodicalIF":9.2000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice A narrative review paper.\",\"authors\":\"Tair Ben-Porat, Shiri Sherf-Dagan, Marilou Côté, Cherie Josephine Miner, Assaf Buch\",\"doi\":\"10.1016/j.advnut.2025.100522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Several novel incretin-based obesity management medications (OMMs) have been recently approved for chronic weight management in adults with obesity or overweight. These agents have demonstrated substantial weight reduction effects, alongside glucoregulatory and cardioprotective benefits. However, the use of incretin-based OMMs presents nutritional challenges that remain insufficiently addressed. These include side effects such as gastrointestinal (GI) disturbances and loss of lean body mass (LBM), which may compromise nutritional status, reduce energy expenditure, and heighten the risk of rebound weight gain, sarcopenia, and frailty. Moreover, while these medications effectively suppress energy intake and reduce food quantity, they may also have unintended effects on diet quality, potentially influencing macronutrient distribution, ultra processed food consumption, risk of vitamin and mineral deficiencies, and disordered eating behaviors, which could undermine long-term weight maintenance and the cardiometabolic benefits achieved through these pharmacotherapy agents. Emerging evidence suggests that specific dietary and behavioral strategies, such as higher protein intake, resistance training, nutrient-dense eating patterns, and fostering adaptive eating behaviors, may help mitigate nutritional challenges and physiological deterioration during significant weight reduction, while also supporting cardiometabolic health maintenance. However, the application of these strategies as adjunct treatments alongside the new OMMs remains unclear. This narrative review summarizes the current literature on these issues and proposes dietary interventions and behavioral modification strategies aimed at mitigating the adverse effects that can be associated with incretin-based OMMs. These considerations are increasingly important given the expanding use of these medications, the degree of weight reduction they induce, and the implications for specific at-risk groups, including aging populations prone to muscle and functional decline, individuals with pre-existing conditions of nutritional deficiencies, chronic diseases, and disordered eating patterns.</p>\",\"PeriodicalId\":72101,\"journal\":{\"name\":\"Advances in nutrition (Bethesda, Md.)\",\"volume\":\" \",\"pages\":\"100522\"},\"PeriodicalIF\":9.2000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in nutrition (Bethesda, Md.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.advnut.2025.100522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in nutrition (Bethesda, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.advnut.2025.100522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

最近,一些新的基于肠促胰岛素的肥胖管理药物(OMMs)被批准用于肥胖或超重成人的慢性体重管理。这些药物已经证明了大量的减肥效果,以及血糖调节和心脏保护的好处。然而,使用基于肠促胰岛素的OMMs带来的营养挑战仍然没有得到充分解决。这些副作用包括胃肠道(GI)紊乱和瘦体重(LBM)下降,这可能会损害营养状况,减少能量消耗,并增加反弹体重增加、肌肉减少和虚弱的风险。此外,虽然这些药物有效地抑制能量摄入和减少食物量,但它们也可能对饮食质量产生意想不到的影响,可能影响宏量营养素的分布、超加工食品的消费、维生素和矿物质缺乏的风险以及饮食行为紊乱,这可能会破坏这些药物治疗药物实现的长期体重维持和心脏代谢益处。新出现的证据表明,特定的饮食和行为策略,如高蛋白质摄入、抗阻训练、营养密集的饮食模式和培养适应性饮食行为,可能有助于减轻显著减肥期间的营养挑战和生理恶化,同时也支持心脏代谢健康的维持。然而,这些策略作为辅助治疗与新的OMMs的应用仍不清楚。本文总结了目前关于这些问题的文献,并提出了饮食干预和行为改变策略,旨在减轻与基于肠促胰岛素的OMMs相关的不良反应。考虑到这些药物的广泛使用,它们引起的体重减轻程度,以及对特定风险群体的影响,这些考虑变得越来越重要,这些风险群体包括容易出现肌肉和功能衰退的老年人,先前患有营养缺乏、慢性疾病和饮食模式紊乱的个体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice A narrative review paper.

Several novel incretin-based obesity management medications (OMMs) have been recently approved for chronic weight management in adults with obesity or overweight. These agents have demonstrated substantial weight reduction effects, alongside glucoregulatory and cardioprotective benefits. However, the use of incretin-based OMMs presents nutritional challenges that remain insufficiently addressed. These include side effects such as gastrointestinal (GI) disturbances and loss of lean body mass (LBM), which may compromise nutritional status, reduce energy expenditure, and heighten the risk of rebound weight gain, sarcopenia, and frailty. Moreover, while these medications effectively suppress energy intake and reduce food quantity, they may also have unintended effects on diet quality, potentially influencing macronutrient distribution, ultra processed food consumption, risk of vitamin and mineral deficiencies, and disordered eating behaviors, which could undermine long-term weight maintenance and the cardiometabolic benefits achieved through these pharmacotherapy agents. Emerging evidence suggests that specific dietary and behavioral strategies, such as higher protein intake, resistance training, nutrient-dense eating patterns, and fostering adaptive eating behaviors, may help mitigate nutritional challenges and physiological deterioration during significant weight reduction, while also supporting cardiometabolic health maintenance. However, the application of these strategies as adjunct treatments alongside the new OMMs remains unclear. This narrative review summarizes the current literature on these issues and proposes dietary interventions and behavioral modification strategies aimed at mitigating the adverse effects that can be associated with incretin-based OMMs. These considerations are increasingly important given the expanding use of these medications, the degree of weight reduction they induce, and the implications for specific at-risk groups, including aging populations prone to muscle and functional decline, individuals with pre-existing conditions of nutritional deficiencies, chronic diseases, and disordered eating patterns.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信